Alzheimer’s Disease Market to Observe Stupendous Growth During the Forecast Period (2019-32) | Companies – Eisai, Cerecin, Otsuka, Neurimmune, BioArctic, Roche, AZ Therapies, and Others
The Alzheimer’s Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Alzheimer’s Disease: An Overview
Alzheimer’s disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer’s patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.
Nearly one-half of patients with Alzheimer’s disease have moderate to severe disease (Yuan et al. 2021). Among people with Alzheimer’s disease, 50.4% had mild disease, 30.3% had moderate disease, and 19.3% had severe disease. This means that half of all cases could be categorized as mild.
Some of the laboratory tests for diagnosing Alzheimer’s Disease include magnetic resonance imaging (MRI), computerized tomography (CT) scan, Flurodeoxyglucose positron emission tomography (PET), and Tau PET imaging. Researchers are working to develop tests that can measure biological signs of disease processes in the brain.
Alzheimer’s Disease Market Key Facts
-
In 2020, as many as around 6 million Americans were living with Alzheimer’s disease and it was observed that younger people may get Alzheimer’s disease, but it is less common. It was also noted that the number of people living with the disease doubles every 5 years beyond age 65 (Centers for Disease Control and Prevention, 2020).
-
As per Alzheimer’s Association (2021), women are disproportionately affected by Alzheimer’s disease. More women than men have Alzheimer’s or other dementias. Almost two-thirds of Americans with Alzheimer’s are women. Of the 6.2 million people age 65 and older with Alzheimer’s in the United States, 3.8 million are women and 2.4 million are men. This represents 12% of women and 9% of men age 65 and older in the United States.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Alzheimer’s Disease market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Alzheimer’s Disease market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Alzheimer’s Disease Epidemiology
The epidemiology section covers insights into the historical and current Alzheimer’s Disease patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Alzheimer’s Disease Epidemiology Segmentation
-
Total prevalent cases of Alzheimer’s Disease (AD)
-
Total diagnosed prevalent cases of Alzheimer’s disease
-
Total gender-specific diagnosed prevalent cases of Alzheimer’s Disease
-
Total age-specific diagnosed prevalent cases of Alzheimer’s Disease
-
Total treated cases of Alzheimer’s Disease
Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alzheimer’s Disease market or expected to get launched in the market during the study period. The analysis covers Alzheimer’s Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Alzheimer’s Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market
Alzheimer’s Disease Therapeutics Analysis
The Alzheimer’s Disease market dynamics is anticipated to change in the coming years owing to the improvement in healthcare spending across the world. Several key players at the global level are involved in developing drugs for Alzheimer’s Disease.
Some of the key companies in the Alzheimer’s Disease Market include:
-
Eisai
-
Cerecin
-
Neurimmune
-
BioArctic AB
-
Hoffmann-La Roche
-
Chugai Pharmaceuticals
-
Anavex Life Sciences Corp.
-
Reviva Pharmaceutical
-
AZ Therapies
-
Otsuka Pharmaceutical
And others
Alzheimer’s Disease Therapies covered in the report include:
-
RP5063
-
ALZT-OP1
-
Tricaprilin
-
Gantenerumab
-
Tricaprilin
-
Brexpiprazole
-
Lecanemab (BAN2401)
-
Aducanumab (BIIB037)
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market
Table of Content (ToC)
1. Key Insights
2. Executive Summary
3. Alzheimer’s Disease Competitive Intelligence Analysis
4. Alzheimer’s Disease Market Overview at a Glance
5. Alzheimer’s Disease Disease Background and Overview
6. Alzheimer’s Disease Patient Journey
7. Alzheimer’s Disease Epidemiology and Patient Population
8. Alzheimer’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Alzheimer’s Disease Unmet Needs
10. Key Endpoints of Alzheimer’s Disease Treatment
11. Alzheimer’s Disease Marketed Products
12. Alzheimer’s Disease Emerging Therapies
13. Alzheimer’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Alzheimer’s Disease Market Outlook (7 major markets)
16. Alzheimer’s Disease Access and Reimbursement Overview
17. KOL Views on the Alzheimer’s Disease Market.
18. Alzheimer’s Disease Market Drivers
19. Alzheimer’s Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market
Other Latest Reports By DelveInsight
DelveInsight’s “Follicular Lymphoma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
 | Companies – Eisai, Cerecin, Otsuka, Neurimmune, BioArctic, Roche, AZ Therapies, and Others){kind=link}